TNF-α converting enzyme (TACE or ADAM17; EC 184.108.40.206), a pro-inflammatory cytokine, catalyzes the formation of TNF-α from membrane bound TNF-α precursor protein. It is is believed to play pathophysiological roles in inflammation, anorexia, cachexia, septic shock, viral replication and so on. What’s more, TNF-α is a key player in inflammation and joint damage in rheumatoid arthritis. To control the level of TNF-α release, inhibition of TACE activity has long been considered as a promising way of treating related inflammatory diseases for which one of the most attractive strategies is the development of low molecular mass inhibitors of TACE.
 P.R. Murumkar et al. Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opin. Ther. Pat. 2010, 20, 31-57.